


Eye screening powered by AI to transform primary care

Professor Angus Turner



Photo credits: "[Lightning storm off Cooke Point, Port Hedland, Australia](#)" by [DrWang86](#) is licensed under [CC BY 2.0](#). / "[Dampier Salt evaporation flats, Port Hedland, 2023, 11](#)" by [Kgbo](#) is licensed under [CC BY-SA 4.0](#).





Are you worried?
We need to know.
If you, or the person you care for, gets worse, fall or have any
problems, please call us on 1800 431 143.
We'll be there for you.

OPERATION
TREAT

Country Health Service
of Western Australia
Pilbara







Chronic shortage of ophthalmology and optometry workforce

30% of Aboriginal people have Diabetes in the northwest

98% vision loss from Diabetic Retinopathy is preventable

20% get recommended eye screening

Past efforts for screening in primary care have failed

Technology trip-hazards prevent uptake

MBS Item numbers for DR Screening – 9 years

Item	Australia	WA
12325	8493	3500
12326	7498	5069

But there are 1.3 million patients living with Diabetes in Australia... ?

**Please share your perspective on AI
supported DR screening**





Take the photo




Photo assessed



Follow up care



???






Not all populations and settings are the same..

Subgroup	Sensitivity (% , 95% CI)	Specificity (% , 95% CI)	AUC (% , 95% CI)
<i>Diabetes type</i>			
Type 1	100.0 [39.8–100.0]	90.9 [81.3–96.6]	0.96 [0.92–0.99]
Type 2	96.4 [81.7–99.9]	85.3 [76.9–91.5]	0.91 [0.86–0.96]
<i>Clinic</i>			
Endocrinology	100.0 [71.5–100.0]	91.5 [85.6–95.5]	0.96 [0.93–0.98]
Aboriginal medical service	95.2 [76.1–99.9]	70.0 [4.86–81.4]	0.83 [0.73–0.92]
<i>Camera model</i>			
Canon	100.0 [59.0–100.0]	90.7 [82.5–95.9]	0.95 [0.92–0.98]
DRS	100.0 [63.1–100.0]	91.4 [82.3–96.8]	0.96 [0.92–0.99]
Topcon Maestro	94.1 [71.3–99.9]	53.3 [26.6–78.7]	0.74 [0.59–0.88]

Table 4. Sub-group analysis (n = 203).



Validation of a deep learning system for the detection of diabetic retinopathy in Indigenous Australians

Mark A Chia ,^{1,2,3} Fred Hersch,⁴ Rory Sayres,⁴ Pinal Bavishi,⁴ Richa Tiwari,⁴ Pearse A Keane ,^{1,2} Angus W Turner ^{3,5}

PROOF OF CONCEPT

- Google AI was clear winner (n=317)
 - 100% sensitivity
 - 97.5% gradable
- Positive patient and stakeholder evaluation towards the use of AI
- 17 times more people screened

The screenshot displays the ARDA interface with the following elements:

- Google** logo at the top left.
- ARDA: Automated Retinal Disease Assessment title.
- A "CHOOSE IMAGE" button.
- Text: "Drag another image to analyze or".
- FILE NAME (SIZE): "Uploaded retina image jpg (2.11M)".
- DIAGNOSIS ID: "drw-2062".
- A large circular fundus image of the retina.
- DIAGNOSIS: "MODERATE DIABETIC RETINOPATHY REFERRABLE".
- A horizontal bar chart for "MODERATE DIABETIC RETINOPATHY REFERRABLE" with a red bar extending to approximately 0.50 on a scale from 0.00 to 1.00. The text "Moderate Severe or Proliferative" is overlaid on the bar.
- DIAGNOSIS: "DIABETIC MACULAR OEDEMA GRADE".
- A horizontal bar chart for "DIABETIC MACULAR OEDEMA GRADE" with a red bar extending to approximately 0.85 on a scale from 0.00 to 1.00. The text "Referrable DME" is overlaid on the bar.
- DIAGNOSIS: "DIABETIC RETINOPATHY GRADE".
- A vertical bar chart showing the distribution of the overall grade. The y-axis ranges from 0.00 to 1.00. The x-axis categories are None, Mild, Moderate, Severe, and Proliferative. A yellow bar is positioned at the "Moderate" category, reaching a height of approximately 0.85.

A new retinal camera

**Remote nurse or health worker
takes the photo opportunistically
when seeing patient**

**AI provides on the spot diagnosis
and health assessment**

**Immediate consult with
specialist or GP as required via
telehealth**





ORIGINAL RESEARCH **OPEN ACCESS**

Implementation of A New, Mobile Diabetic Retinopathy Screening Model Incorporating Artificial Intelligence in Remote Western Australia

Qiang Li¹  | Jocelyn J. Drinkwater^{1,2} | Kerry Woods¹ | Emma Douglas¹ | Alex Ramirez¹ | Angus W. Turner^{1,2}

¹Lions Eye Institute, Lions Outback Vision, Nedlands, Western Australia, Australia | ²Centre for Ophthalmology and Visual Science, The University of Western Australia, Crawley, Australia

Correspondence: Angus W. Turner (angus.turner@uwa.edu.au)

Received: 30 October 2024 | **Revised:** 18 February 2025 | **Accepted:** 12 March 2025

Funding: This activity was supported by the Western Australian Future Health Research and Innovation Fund (grant ID DoH202310626/1), the McCusker Charitable Foundation, and the Fred Hollows Foundation.

Keywords: deep learning system | diabetes mellitus | diabetic retinopathy | remote | screening

ABSTRACT

Objective: Diabetic retinopathy (DR) screening rates are poor in remote Western Australia where communities rely on outdated

Partners on the ground



Funders



Reimagining regional and remote health care



The McCusker Charitable Foundation









Technology partners (in kind)



Research partners





The Epidemic of Heart Failure...

1 in 10

1 in 10 people over the age of 40 will develop Heart Failure in their lifetime^{1,4,5}

30%

30% of patients will die within 1 year of Heart Failure hospitalization^{1,8,9}

46%

Heart Failure diagnoses are expected to **rise by 46%** by the year 2030¹³


\$108B

Heart Failure costs the world economy **\$108B each year**, and hospitalizations comprise 60-70% of direct treatment costs^{1,10,11,12}

#1

Heart Failure is the **#1 reason for hospitalizations** for people over 65^{1,6,7}

Heart Failure impact on Quality of Life



Heart failure limits length of life and profoundly impacts function and quality of life¹

¹ Goodlin, S. J Am Coll Cardiol 2009;54:386-96.

New diagnostic frontiers

Article

A foundation model for generalizable disease detection from retinal images

<https://doi.org/10.1038/s41586-023-06555-x>

Received: 5 December 2022

Accepted: 18 August 2023

Published online: 13 September 2023


Open access

 Check for updates

Yukun Zhou^{1,2,3}✉, Mark A. Chia^{2,4}, Siegfried K. Wagner^{2,4}, Murat S. Ayhan^{1,2,4},
Dominic J. Williamson^{1,2,4}, Robert R. Struven^{1,2,4}, Tingting Liu², Moucheng Yu^{1,3},
Mateo G. Lozano^{2,5}, Pete Consortium*, Andre Alt*, Daniel C. Alexander^{1,12} &


Medical artificial intelligence conditions in retinal in disorders¹. However, t and models are usually applications². Here, w learns generalizable re basis for label-efficient

Stage 1: Self-supervision on retinal images



↑
MEH-MIDAS +
public datasets

Stage 2: Supervised fine-tuning for clinical tasks



And more... EyeFound and VisionFM

- EyeFound: Trained on 2.78 million images from 227 hospitals across
- 11 ophthalmic modalities,
- Even for detecting challenging rare diseases.
- Outperforms previous work RETFound

- VisionFM
- 3.4 million images from 500,000 individuals
- 12 diseases

Foundation Model - now to 'fine-tuning'





<https://doi.org/10.1038/s41746-025-01436-1>

Real-world feasibility and acceptability of retinal photography for disease risk assessment in primary care

A list of authors and their affiliations is available in the full text of the article.

We aim to assess the real-world feasibility and acceptability (secondary outcomes) of an automated retinal photography (CVD) risk assessment tool. Participants aged 45–70 years who were recruited from two general practices underwent retinal imaging. A CVD risk score was generated by a deep learning model. The World Health Organisation (WHO) CVD risk score was used as a reference.

Population impact and cost-effectiveness of artificial intelligence-based diabetic retinopathy screening in people living with diabetes in Australia: a population-based cohort study

Wenyi Hu,^{a,b} Sanil Joseph,^{a,b} Rui Li,^{d,e,i} Ekaterina Woods,^{a,b} Jason Sun,^f Mingwan Mingguang He,^{a,b,g,h,**} and Lei Zhang^{c,a,d,e,*}

^aCentre for Eye Research Australia, Royal Victorian Eye and Ear Hospital

^bDepartment of Surgery (Ophthalmology), The University of Melbourne

^cClinical Medical Research Center, Children's Hospital of Nanjing Medical University

^dCentral Clinical School, Faculty of Medicine, Monash University, Melbourne

^eArtificial Intelligence and Modelling in Epidemiology Program, Melbourne School of Engineering, The University of Melbourne, Australia

^fEyetelligence Pty Ltd., Melbourne, Australia

^gSchool of Optometry, The Hong Kong Polytechnic University, Hong Kong

^hResearch Centre for SHARP Vision, The Hong Kong Polytechnic University

ⁱChina-Australia Joint Research Center for Infectious Diseases, School of Public Health, Xi'an, Shaanxi, 710061, PR China

Summary

Background We aimed to evaluate the cost-effectiveness of an artificial intelligence (AI)-based diabetic retinopathy (DR) screening system in the primary care setting for both type 1 and type 2 diabetes in Australia.

Methods We performed a cost-effectiveness analysis between an AI-based DR screening system and a standard of care. An analytic Markov model was constructed to simulate DR progression in 65,160 Indigenous Australians living with diabetes at baseline.

Articles

Tseng et al. *BMC Medicine* (2023) 21:28
<https://doi.org/10.1186/s12916-022-02684-8>

BMC Medicine

RESEARCH ARTICLE

Open Access



Validation of a deep-learning-based retinal biomarker (Reti-CVD) in the prediction of cardiovascular disease: data from UK Biobank

Rachel Marjorie Wei Wen Tseng^{1,2†}, Tyler Hyungtaek Rim^{1,3,4*†}, Eduard Shantsila⁵, Joseph K. Yi⁶, Sungha Park⁷, Sung Soo Kim⁸, Chan Joo Lee⁷, Sahil Thakur¹, Simon Nusinovi^{1,3}, Qingsheng Peng^{1,9}, Hyeonmin Kim⁴, Geunyoung Lee⁴, Marco Yu^{1,3}, Yih-Chung Tham^{1,3,10,11}, Ameet Bakhai^{12,13}, Paul Leeson¹⁴, Gregory Y.H. Lip¹⁵, Tien Yin Wong^{1,16} and Ching-Yu Cheng^{1,3,10,11}

Abstract

Background Currently in the United Kingdom, cardiovascular disease (CVD) risk assessment is based on the QRISK3 score, in which 10% 10-year CVD risk indicates clinical intervention. However, this benchmark has limited efficacy in clinical practice and the need for a more simple, non-invasive risk stratification tool is necessary. Retinal photography is becoming increasingly acceptable as a non-invasive imaging tool for CVD. Previously, we developed a novel CVD risk assessment tool (Reti-CVD) based on deep learning. We aimed to validate the performance of Reti-CVD in the prediction of CVD in the UK Biobank.

The Economist

Modi's secret weapon

Corpulent consultancies

Trump and the world

Antarctica loses its brrrr

MARCH 30TH-APRIL 5TH 2024

**The AI doctor will see you
...eventually**



Is AI for DR diagnosis any use for you?





